FOSUN TIMES 2013.4.30 … · 2013-05-09 · Senior Vice President of Fosun Pharma. Wanbang Pharma...

1
FOSUN TIMES 2013.4.30 News 04 ByYiJinyuan FOSUNTIMESSubsequentto its listing in Hong Kong, Fosun Pharma strategically became more focused on development in pharmaceutical manufacturing with a strategic development modelof internalgrowth,exter- nal expansion and integrated de- velopment. Recently,Fosun Pharma ac- celerated integration of strategic cardiovascular product supply chains. Wanbang Pharma, one of itssubsidiaries,acquired51%eq- uity of Zaozhuang Sainuokang and actively engaged in interna- tional development through co- operation with the German com- panyBiotestandtheUScompany Saladax, by which expanded a- gain cooperation models with outstanding overseas pharmaceu- tical firms and comprehensively enhanced competitiveness in the industry. AsamajorsubsidiaryofFo- sun Pharma, Wanbang Pharma adheredtoadevelopmentalstrat- egyofdualdirectionsfromone centrein positioning itself, meaning centering around dia- betes medicines while expanding into cardiovascular and anti-can- cer medicines. Wanbang Pharma is the largest sodium heparin in- jection manufacturer in China and a leading low molecular weight heparin injection manu- facturerinthecountry.Heparinis a substance extracted from porcine small intestinal mucus possessing anticoagulant effect and is widely used in preventing andtreatingvariousdiseases,Itis a bio-medicine with the largest salesacrosstheworldandanan- ticoagulantthemostused.InChi- na,acountryaccountingformost of the manufacture and exporta- tion of its raw material, it occu- pies an important position in medicineexport. Sainuokang Biochemical, a company specialized in produc- tionofheparinAPI,hasaleading position in China with its new method,technologyandcostcon- trol. Through strategic coopera- tion with Ruicheng, Wanbang Pharma obtained control over SainuokangBiochemical,thereby ensuringstablesupply of sodium heparin API and lowered pur- chase cost of API.Li Xianlin, Senior Vice President of Fosun Pharma. Wanbang Pharma also en- tered into an agreement with the German company Biotest in Shanghai recently. A product of Biotest,isexclusivelydistributed byWanbangPharmaintheMain- land China region. Sales of hu- man serum albumin of Chinese hospital market amounted to ap- proximately RMB3.5 billion in 2011. Humanserumalbuminisan albuminmedicineextractedfrom blood of healthy human, mainly usedintreatmentofbleedingand wound, shock caused by burns, high intracranial pressure caused bycerebraledemaorinjury,ede- maor ascites caused by cirrhosis andkidneydisease,andiswidely usedinclinicalemergency.Inre- centyears,demandofitincreased in the market of China, where there were shortages of related productsintimes.Biotest,aglob- ally leading company of blood and bio-product research and de- velopment and manufacture, was founded in 1946, has been listed on Frankfurt Stock Exchange since 1987 and was included in Deutsche Brse SDAX index in 2007. The company possesses outstanding techniques in maxi- mizing separation and purifica- tion of high-value medicinal in- gredients, where the techniques arethoseofhighstandardsincol- lection, testing and manufactur- ingofplasmatoensurestableand reliable quality. This cooperation willcontributetoalleviatingtight supply of human serum albumin in the market of China and pro- duceagreatsocialeffect. In addition, Fosun Pharma announced its entering into a se- ries of cooperative agreements with the US company Saladax Biomedical, Inc. to subscribe for batchDofadditionalpreferential shares of Saladax at a considera- tion of approximately USD22.5 million.Uponcompletionofsuch subscription, Fosun Pharma will be the sole majority shareholder thereof. Also, Shanghai Fosun LongMarchMedicalScienceCo. ,Ltd,asubsidiaryofFosunPhar- ma,enteredintoastrategiccoop- erative agreement with Saladax, therebyobtainedexclusivedistri- bution right and product manu- facturerightwithinChina. Saladax possesses advanced testing technology and chemotherapy medicine monitor- ingproductportfolio.Suchcoop- eration will effectively enhance innovative capability of Fosun Pharmainmedicaldiagnosisand enable development of a bio-test platform in China, and even the international market, capable of testing concentration and other parameters of chemotherapy medicinessoastobetteranalysis effectofsuchmedicinesintreat- ments. It is expected that such productlinewillobtainconsider- ablesalesscaleinChina.PFL Sales Office in Jiujiang Road Opened for Business ByFloraShao FOSUN TIMES [April 16, 2013Shanghai]PramericaFosun Life Insurance (PFL) staged a grand opening ceremony for the JiujiangRoadSalesOfficeinthe Financial Plaza, Huangpu Dis- trict. Shareholder/Prudential rep- resentatives Bob Fallon, Senior VicePresident,BartholomewNg, Managing Director of China and Gaurang Pandya, Vice President of International Department joined the opening ceremony to- getherwithPFL General Manag- erWilsonYeungandothersenior managers. During the ceremony, Steven Zhou, Tied Agency Head of PFL delivered the opening re- marks by thanking all colleagues andpartnersfortheircontribution to the channel; he also encour- aged all to join hand together to achievenewhigh. Amiddrumbeats,twogiant lions mounted on the stage and started to dance, culminating at theeye-dottingceremony,itsug- gestPFLasawakinglionfullof power,boundtogrowstronger. Three shareholder represen- tatives, Wilson Yeung, Steven Zhou of Tied Agency and Haidong Shen of Bancassurance jointly unveiled the sales office. Whiletheredribbonwasdrawn and the salute was fired, a roll printed with "Ambitious Devel- opment and Booming Business" cameoutfromthemouthofthe lions,itrepresentsthebestwish- esofallguestsforarosyfuture ofPFLfromallguest. Wilson,Bartandsharehold- errepresentativesmadespeeches inorder;theysawthedayasan important moment for PFL as thisisthefirstsalesofficeofthe company.Withtheexpansionof thecompanyandthestaff,more sales offices will be opened to meet customers' needs. Both shareholders are ready to pro- videmoresupportandresources to the company, they highly praised and recognized the joint effortsoftheentirestaff,andal- soexpressedhighexpectationon the further development of the channels. To celebrate such a mean- ingful moment, all guests opened champagne of success and had a toast for all partners. Steven, Haidong and channel representatives cut a cake to mark the successful opening of the sales office and wished PFL ever-betterperformance. FosunPharmafocusesonstrategicdevelopment toaccelerateinternationalcooperation

Transcript of FOSUN TIMES 2013.4.30 … · 2013-05-09 · Senior Vice President of Fosun Pharma. Wanbang Pharma...

Page 1: FOSUN TIMES 2013.4.30 … · 2013-05-09 · Senior Vice President of Fosun Pharma. Wanbang Pharma also en-teredintoanagreementwiththe German company Biotest in Shanghairecently.Aproductof

FOSUN TIMES 2013.4.30

News

04

By�Yi�Jinyuan

■ FOSUN�TIMES�Subsequent�to�

its� listing� in� Hong� Kong,� Fosun�

Pharma� strategically� became�

more� focused�on�development� in�

pharmaceutical� manufacturing�

with� a� strategic� development�

model�of�“internal�growth,�exter-

nal� expansion� and� integrated� de-

velopment”.

Recently,�Fosun�Pharma�ac-

celerated� integration� of� strategic�

cardiovascular� product� supply�

chains.�Wanbang�Pharma,�one�of�

its�subsidiaries,�acquired�51%�eq-

uity� of� Zaozhuang� Sainuokang�

and� actively� engaged� in� interna-

tional� development� through� co-

operation�with� the�German� com-

pany�Biotest�and�the�US�company�

Saladax,� by� which� expanded� a-

gain� cooperation� models� with�

outstanding� overseas� pharmaceu-

tical� firms� and� comprehensively�

enhanced� competitiveness� in� the�

industry.

As�a�major�subsidiary�of�Fo-

sun� Pharma,� Wanbang� Pharma�

adhered�to�a�developmental�strat-

egy�of�“dual�directions�from�one�

centre” in� positioning� itself,�

meaning� centering� around� dia-

betes�medicines�while� expanding�

into� cardiovascular� and� anti-can-

cer�medicines.�Wanbang� Pharma�

is� the� largest� sodium� heparin� in-

jection� manufacturer� in� China�

and� a� leading� low� molecular�

weight� heparin� injection� manu-

facturer�in�the�country.�Heparin�is�

a� substance� extracted� from�

porcine� small� intestinal� mucus�

possessing� anticoagulant� effect�

and� is�widely� used� in� preventing�

and�treating�various�diseases,�It�is�

a� bio-medicine� with� the� largest�

sales�across�the�world�and�an�an-

ticoagulant�the�most�used.�In�Chi-

na,�a�country�accounting�for�most�

of� the� manufacture� and� exporta-

tion� of� its� raw�material,� it� occu-

pies� an� important� position� in�

medicine�export.

Sainuokang� Biochemical,� a�

company� specialized� in� produc-

tion�of�heparin�API,�has�a�leading�

position� in� China� with� its� new�

method,�technology�and�cost�con-

trol.�“Through� strategic� coopera-

tion� with� Ruicheng,� Wanbang�

Pharma� obtained� control� over�

Sainuokang�Biochemical,�thereby�

ensuring�stable�supply�of� sodium�

heparin� API� and� lowered� pur-

chase� cost� of� API.” Li� Xianlin,�

Senior� Vice� President� of� Fosun�

Pharma.

Wanbang� Pharma� also� en-

tered� into� an� agreement�with� the�

German� company� Biotest� in�

Shanghai� recently.� A� product� of�

Biotest,� is�exclusively�distributed�

by�Wanbang�Pharma�in�the�Main-

land� China� region.� Sales� of� hu-

man� serum� albumin� of� Chinese�

hospital�market� amounted� to� ap-

proximately� RMB3.5� billion� in�

2011.

Human�serum�albumin�is�an�

albumin�medicine�extracted�from�

blood� of� healthy� human,� mainly�

used�in�treatment�of�bleeding�and�

wound,� shock� caused� by� burns,�

high� intracranial� pressure� caused�

by�cerebral�edema�or�injury,�ede-

ma�or� ascites� caused� by� cirrhosis�

and�kidney�disease,�and�is�widely�

used�in�clinical�emergency.�In�re-

cent�years,�demand�of�it�increased�

in� the� market� of� China,� where�

there� were� shortages� of� related�

products�in�times.�Biotest,�a�glob-

ally� leading� company� of� blood�

and�bio-product� research�and�de-

velopment� and�manufacture,�was�

founded� in� 1946,� has� been� listed�

on� Frankfurt� Stock� Exchange�

since� 1987� and� was� included� in�

Deutsche� B觟rse� SDAX� index� in�

2007.� The� company� possesses�

outstanding� techniques� in� maxi-

mizing� separation� and� purifica-

tion� of� high-value� medicinal� in-

gredients,� where� the� techniques�

are�those�of�high�standards�in�col-

lection,� testing� and� manufactur-

ing�of�plasma�to�ensure�stable�and�

reliable�quality.�This�cooperation�

will�contribute�to�alleviating�tight�

supply� of� human� serum� albumin�

in� the�market� of� China� and� pro-

duce�a�great�social�effect.

In� addition,� Fosun� Pharma�

announced� its� entering� into� a� se-

ries� of� cooperative� agreements�

with� the� US� company� Saladax�

Biomedical,� Inc.� to� subscribe� for�

batch�D�of�additional�preferential�

shares�of�Saladax�at� a� considera-

tion� of� approximately� USD22.5�

million.�Upon�completion�of�such�

subscription,� Fosun� Pharma� will�

be� the� sole� majority� shareholder�

thereof.� Also,� Shanghai� Fosun�

Long�March�Medical�Science�Co.

,�Ltd,�a�subsidiary�of�Fosun�Phar-

ma,�entered�into�a�strategic�coop-

erative� agreement� with� Saladax,�

thereby�obtained�exclusive�distri-

bution� right� and� product� manu-

facture�right�within�China.

Saladax� possesses� advanced�

testing� technology� and�

chemotherapy�medicine�monitor-

ing�product�portfolio.�Such�coop-

eration� will� effectively� enhance�

innovative� capability� of� Fosun�

Pharma�in�medical�diagnosis�and�

enable� development� of� a� bio-test�

platform� in� China,� and� even� the�

international� market,� capable� of�

testing� concentration� and� other�

parameters� of� chemotherapy�

medicines�so�as�to�better�analysis�

effect�of�such�medicines� in� treat-

ments.� It� is� expected� that� such�

product�line�will�obtain�consider-

able�sales�scale�in�China.■

PFL Sales Office in Jiujiang Road Opened for Business

By�Flora�Shao

■ FOSUN� TIMES� [April� 16,�

2013�Shanghai]�Pramerica�Fosun�

Life� Insurance� (PFL)� staged� a�

grand� opening� ceremony� for� the�

Jiujiang�Road�Sales�Office� in� the�

Financial� Plaza,� Huangpu� Dis-

trict.� Shareholder/Prudential� rep-

resentatives� Bob� Fallon,� Senior�

Vice�President,�Bartholomew�Ng,�

Managing�Director� of�China� and�

Gaurang� Pandya,� Vice� President�

of� International� Department�

joined� the� opening� ceremony� to-

gether�with�PFL�General�Manag-

er�Wilson�Yeung�and�other�senior�

managers.��

During� the� ceremony,�

Steven�Zhou,�Tied�Agency�Head�

of�PFL�delivered� the�opening� re-

marks�by� thanking�all� colleagues�

and�partners�for�their�contribution�

to� the� channel;� he� also� encour-

aged� all� to� join� hand� together� to�

achieve�new�high.

Amid�drum�beats,�two�giant�

lions� mounted� on� the� stage� and�

started� to� dance,� culminating� at�

the�eye-dotting�ceremony,�it�sug-

gest�PFL�as�a�waking�lion�full�of�

power,�bound�to�grow�stronger.��

Three� shareholder� represen-

tatives,� Wilson� Yeung,� Steven�

Zhou� of� Tied� Agency� and�

Haidong� Shen� of� Bancassurance�

jointly� unveiled� the� sales� office.�

While� the� red� ribbon�was�drawn�

and� the� salute� was� fired,� a� roll�

printed� with� "Ambitious� Devel-

opment� and� Booming� Business"�

came�out� from� the�mouth�of� the�

lions,�it�represents�the�best�wish-

es�of� all� guests� for� a� rosy� future�

of�PFL�from�all�guest.�

Wilson,�Bart�and�sharehold-

er�representatives�made�speeches�

in�order;� they�saw� the�day�as�an�

important� moment� for� PFL� as�

this�is�the�first�sales�office�of�the�

company.�With� the�expansion�of�

the�company�and� the� staff,�more�

sales� offices� will� be� opened� to�

meet� customers'� needs.� Both�

shareholders� are� ready� to� pro-

vide�more� support�and� resources�

to� the� company,� they� highly�

praised� and� recognized� the� joint�

efforts�of�the�entire�staff,�and�al-

so�expressed�high�expectation�on�

the� further� development� of� the�

channels.��

To� celebrate� such� a� mean-

ingful� moment,� all� guests�

opened� champagne� of� success�

and� had� a� toast� for� all� partners.�

Steven,� Haidong� and� channel�

representatives� cut� a� cake� to�

mark� the� successful� opening� of�

the� sales� office� and�wished� PFL�

ever-better�performance.�■

Fosun�Pharma�focuses�on�strategic�development�

to�accelerate�international�cooperation